EP1161536A1 - Menschliche proteine mit hydrofoben domänen und dnas dafür kodierend - Google Patents

Menschliche proteine mit hydrofoben domänen und dnas dafür kodierend

Info

Publication number: EP1161536A1
Authority: EP; European Patent Office
Prior art keywords: protein; present; amino acid; sequences; proteins
Prior art date: 1998-11-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP99972227A

Other languages

English (en)

French (fr)

Inventor

Seishi Kato

Tomoko Kimura

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sagami Chemical Research Institute

Protegene Inc

Original Assignee

Sagami Chemical Research Institute

Protegene Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-11-17

Filing date

1999-11-17

Publication date

2001-12-12

1998-11-17 Priority claimed from JP32625598A external-priority patent/JP2007222001A/ja

1999-11-17 Application filed by Sagami Chemical Research Institute, Protegene Inc filed Critical Sagami Chemical Research Institute

2001-12-12 Publication of EP1161536A1 publication Critical patent/EP1161536A1/de

Status Withdrawn legal-status Critical Current

Links

108090000623 proteins and genes Proteins 0.000 title claims abstract description 702
102000004169 proteins and genes Human genes 0.000 title claims abstract description 668
102000003839 Human Proteins Human genes 0.000 title abstract description 37
108090000144 Human Proteins Proteins 0.000 title abstract description 37
230000002209 hydrophobic effect Effects 0.000 title abstract description 15
210000003527 eukaryotic cell Anatomy 0.000 claims abstract description 18
239000013604 expression vector Substances 0.000 claims abstract description 16
239000002299 complementary DNA Substances 0.000 claims description 190
238000013519 translation Methods 0.000 claims description 80
238000000338 in vitro Methods 0.000 claims description 49
125000003275 alpha amino acid group Chemical group 0.000 claims 1
108020004414 DNA Proteins 0.000 abstract description 30
235000018102 proteins Nutrition 0.000 description 662
210000004027 cell Anatomy 0.000 description 123
125000000539 amino acid group Chemical group 0.000 description 122
238000000034 method Methods 0.000 description 104
150000001413 amino acids Chemical class 0.000 description 83
230000014616 translation Effects 0.000 description 80
230000036961 partial effect Effects 0.000 description 53
230000000694 effects Effects 0.000 description 52
108091026898 Leader sequence (mRNA) Proteins 0.000 description 51
108091036066 Three prime untranslated region Proteins 0.000 description 51
239000000047 product Substances 0.000 description 51
230000015572 biosynthetic process Effects 0.000 description 49
102000040430 polynucleotide Human genes 0.000 description 39
108091033319 polynucleotide Proteins 0.000 description 39
239000002157 polynucleotide Substances 0.000 description 39
238000003556 assay Methods 0.000 description 32
210000001519 tissue Anatomy 0.000 description 31
210000001744 T-lymphocyte Anatomy 0.000 description 30
230000003248 secreting effect Effects 0.000 description 24
230000014509 gene expression Effects 0.000 description 23
239000003446 ligand Substances 0.000 description 23
102000005962 receptors Human genes 0.000 description 21
108020003175 receptors Proteins 0.000 description 21
239000000427 antigen Substances 0.000 description 19
102000036639 antigens Human genes 0.000 description 19
108091007433 antigens Proteins 0.000 description 19
108090000765 processed proteins & peptides Proteins 0.000 description 19
238000011282 treatment Methods 0.000 description 19
230000006870 function Effects 0.000 description 18
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
210000002435 tendon Anatomy 0.000 description 16
108020004635 Complementary DNA Proteins 0.000 description 14
102000004127 Cytokines Human genes 0.000 description 14
108090000695 Cytokines Proteins 0.000 description 14
201000008808 Fibrosarcoma Diseases 0.000 description 14
101000903791 Homo sapiens Procollagen galactosyltransferase 2 Proteins 0.000 description 14
102100022973 Procollagen galactosyltransferase 2 Human genes 0.000 description 14
230000035755 proliferation Effects 0.000 description 14
230000004069 differentiation Effects 0.000 description 13
230000002401 inhibitory effect Effects 0.000 description 13
239000012528 membrane Substances 0.000 description 13
206010028980 Neoplasm Diseases 0.000 description 12
108010076504 Protein Sorting Signals Proteins 0.000 description 12
239000003814 drug Substances 0.000 description 12
230000003993 interaction Effects 0.000 description 12
241000699666 Mus <mouse, genus> Species 0.000 description 11
108091058545 Secretory proteins Proteins 0.000 description 11
102000040739 Secretory proteins Human genes 0.000 description 11
201000010099 disease Diseases 0.000 description 11
230000012010 growth Effects 0.000 description 11
230000028993 immune response Effects 0.000 description 11
206010041823 squamous cell carcinoma Diseases 0.000 description 11
102100026445 A-kinase anchor protein 17A Human genes 0.000 description 10
102000009088 Angiopoietin-1 Human genes 0.000 description 10
108010048154 Angiopoietin-1 Proteins 0.000 description 10
241000244203 Caenorhabditis elegans Species 0.000 description 10
101000718019 Homo sapiens A-kinase anchor protein 17A Proteins 0.000 description 10
108010052285 Membrane Proteins Proteins 0.000 description 10
101710185494 Zinc finger protein Proteins 0.000 description 10
102100023597 Zinc finger protein 816 Human genes 0.000 description 10
230000000903 blocking effect Effects 0.000 description 10
239000003795 chemical substances by application Substances 0.000 description 10
238000003776 cleavage reaction Methods 0.000 description 10
210000004185 liver Anatomy 0.000 description 10
230000007017 scission Effects 0.000 description 10
210000001541 thymus gland Anatomy 0.000 description 10
239000003153 chemical reaction reagent Substances 0.000 description 9
239000012634 fragment Substances 0.000 description 9
210000003041 ligament Anatomy 0.000 description 9
210000001589 microsome Anatomy 0.000 description 9
239000000203 mixture Substances 0.000 description 9
210000004897 n-terminal region Anatomy 0.000 description 9
210000004881 tumor cell Anatomy 0.000 description 9
201000000582 Retinoblastoma Diseases 0.000 description 8
101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 8
230000001413 cellular effect Effects 0.000 description 8
238000011161 development Methods 0.000 description 8
230000018109 developmental process Effects 0.000 description 8
230000002068 genetic effect Effects 0.000 description 8
210000004698 lymphocyte Anatomy 0.000 description 8
238000004519 manufacturing process Methods 0.000 description 8
239000000523 sample Substances 0.000 description 8
241000282412 Homo Species 0.000 description 7
101001106090 Homo sapiens Receptor expression-enhancing protein 5 Proteins 0.000 description 7
102000002746 Inhibins Human genes 0.000 description 7
108010004250 Inhibins Proteins 0.000 description 7
206010025323 Lymphomas Diseases 0.000 description 7
230000004988 N-glycosylation Effects 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
230000003399 chemotactic effect Effects 0.000 description 7
210000003958 hematopoietic stem cell Anatomy 0.000 description 7
210000005260 human cell Anatomy 0.000 description 7
230000001939 inductive effect Effects 0.000 description 7
239000000893 inhibin Substances 0.000 description 7
238000005259 measurement Methods 0.000 description 7
239000002609 medium Substances 0.000 description 7
108010031970 prostasin Proteins 0.000 description 7
230000004936 stimulating effect Effects 0.000 description 7
239000013598 vector Substances 0.000 description 7
208000023275 Autoimmune disease Diseases 0.000 description 6
241000235347 Schizosaccharomyces pombe Species 0.000 description 6
101710151637 Tetraspanin-5 Proteins 0.000 description 6
102100040872 Tetraspanin-5 Human genes 0.000 description 6
210000003719 b-lymphocyte Anatomy 0.000 description 6
210000000988 bone and bone Anatomy 0.000 description 6
230000007547 defect Effects 0.000 description 6
230000001419 dependent effect Effects 0.000 description 6
208000035475 disorder Diseases 0.000 description 6
238000009396 hybridization Methods 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
230000006698 induction Effects 0.000 description 6
239000003112 inhibitor Substances 0.000 description 6
108020004999 messenger RNA Proteins 0.000 description 6
210000000056 organ Anatomy 0.000 description 6
230000001737 promoting effect Effects 0.000 description 6
238000012216 screening Methods 0.000 description 6
238000002054 transplantation Methods 0.000 description 6
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 5
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 5
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 5
208000009329 Graft vs Host Disease Diseases 0.000 description 5
102000043131 MHC class II family Human genes 0.000 description 5
108091054438 MHC class II family Proteins 0.000 description 5
241000124008 Mammalia Species 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
102100029500 Prostasin Human genes 0.000 description 5
102100021077 Receptor expression-enhancing protein 5 Human genes 0.000 description 5
206010052428 Wound Diseases 0.000 description 5
208000027418 Wounds and injury Diseases 0.000 description 5
235000001014 amino acid Nutrition 0.000 description 5
210000004899 c-terminal region Anatomy 0.000 description 5
230000007812 deficiency Effects 0.000 description 5
229940028334 follicle stimulating hormone Drugs 0.000 description 5
238000001415 gene therapy Methods 0.000 description 5
208000024908 graft versus host disease Diseases 0.000 description 5
230000001900 immune effect Effects 0.000 description 5
208000015181 infectious disease Diseases 0.000 description 5
208000014674 injury Diseases 0.000 description 5
239000000463 material Substances 0.000 description 5
244000005700 microbiome Species 0.000 description 5
102000039446 nucleic acids Human genes 0.000 description 5
108020004707 nucleic acids Proteins 0.000 description 5
150000007523 nucleic acids Chemical class 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
230000008439 repair process Effects 0.000 description 5
238000011160 research Methods 0.000 description 5
229910001415 sodium ion Inorganic materials 0.000 description 5
241000894007 species Species 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
230000008733 trauma Effects 0.000 description 5
102000005606 Activins Human genes 0.000 description 4
108010059616 Activins Proteins 0.000 description 4
241000219195 Arabidopsis thaliana Species 0.000 description 4
102000014914 Carrier Proteins Human genes 0.000 description 4
108010078791 Carrier Proteins Proteins 0.000 description 4
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 4
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
102000043129 MHC class I family Human genes 0.000 description 4
108091054437 MHC class I family Proteins 0.000 description 4
102000018697 Membrane Proteins Human genes 0.000 description 4
241001529936 Murinae Species 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
101710197580 Proteolipid protein 2 Proteins 0.000 description 4
102100030486 Proteolipid protein 2 Human genes 0.000 description 4
241000700159 Rattus Species 0.000 description 4
FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000000488 activin Substances 0.000 description 4
239000000872 buffer Substances 0.000 description 4
210000000845 cartilage Anatomy 0.000 description 4
210000000170 cell membrane Anatomy 0.000 description 4
230000001659 chemokinetic effect Effects 0.000 description 4
238000002512 chemotherapy Methods 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
230000006378 damage Effects 0.000 description 4
229940079593 drug Drugs 0.000 description 4
230000002708 enhancing effect Effects 0.000 description 4
230000035558 fertility Effects 0.000 description 4
230000003394 haemopoietic effect Effects 0.000 description 4
230000035876 healing Effects 0.000 description 4
230000011132 hemopoiesis Effects 0.000 description 4
230000002439 hemostatic effect Effects 0.000 description 4
230000001506 immunosuppresive effect Effects 0.000 description 4
238000000099 in vitro assay Methods 0.000 description 4
230000004054 inflammatory process Effects 0.000 description 4
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 4
230000007774 longterm Effects 0.000 description 4
238000010369 molecular cloning Methods 0.000 description 4
230000008569 process Effects 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
238000011069 regeneration method Methods 0.000 description 4
210000003491 skin Anatomy 0.000 description 4
150000003384 small molecules Chemical class 0.000 description 4
239000000243 solution Substances 0.000 description 4
210000000130 stem cell Anatomy 0.000 description 4
230000008093 supporting effect Effects 0.000 description 4
230000017423 tissue regeneration Effects 0.000 description 4
230000004614 tumor growth Effects 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
RAQMSGVCGSJKCL-FOHZUACHSA-N Asn-Gly-Thr Chemical group C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(N)=O RAQMSGVCGSJKCL-FOHZUACHSA-N 0.000 description 3
XEGZSHSPQNDNRH-JRQIVUDYSA-N Asn-Tyr-Thr Chemical group [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XEGZSHSPQNDNRH-JRQIVUDYSA-N 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
206010062016 Immunosuppression Diseases 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
108020004511 Recombinant DNA Proteins 0.000 description 3
206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 3
230000005867 T cell response Effects 0.000 description 3
230000003110 anti-inflammatory effect Effects 0.000 description 3
230000000692 anti-sense effect Effects 0.000 description 3
230000001363 autoimmune Effects 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
230000000747 cardiac effect Effects 0.000 description 3
230000024245 cell differentiation Effects 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
230000008859 change Effects 0.000 description 3
230000001332 colony forming effect Effects 0.000 description 3
230000004940 costimulation Effects 0.000 description 3
210000004748 cultured cell Anatomy 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
102000037865 fusion proteins Human genes 0.000 description 3
108020001507 fusion proteins Proteins 0.000 description 3
210000002865 immune cell Anatomy 0.000 description 3
230000001976 improved effect Effects 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
230000021633 leukocyte mediated immunity Effects 0.000 description 3
230000033001 locomotion Effects 0.000 description 3
239000006166 lysate Substances 0.000 description 3
210000001616 monocyte Anatomy 0.000 description 3
210000000944 nerve tissue Anatomy 0.000 description 3
201000008968 osteosarcoma Diseases 0.000 description 3
210000000496 pancreas Anatomy 0.000 description 3
239000002243 precursor Substances 0.000 description 3
230000002265 prevention Effects 0.000 description 3
230000008929 regeneration Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
210000001995 reticulocyte Anatomy 0.000 description 3
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
230000002537 thrombolytic effect Effects 0.000 description 3
230000000472 traumatic effect Effects 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
OKZOABJQOMAYEC-NUMRIWBASA-N Asn-Gln-Thr Chemical group [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OKZOABJQOMAYEC-NUMRIWBASA-N 0.000 description 2
GFFRWIJAFFMQGM-NUMRIWBASA-N Asn-Glu-Thr Chemical group [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GFFRWIJAFFMQGM-NUMRIWBASA-N 0.000 description 2
SNYCNNPOFYBCEK-ZLUOBGJFSA-N Asn-Ser-Ser Chemical group [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O SNYCNNPOFYBCEK-ZLUOBGJFSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
241000282465 Canis Species 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
102000019034 Chemokines Human genes 0.000 description 2
108010012236 Chemokines Proteins 0.000 description 2
206010010356 Congenital anomaly Diseases 0.000 description 2
241000557626 Corvus corax Species 0.000 description 2
101710088194 Dehydrogenase Proteins 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
206010017533 Fungal infection Diseases 0.000 description 2
101000924552 Homo sapiens Angiopoietin-1 Proteins 0.000 description 2
101001130763 Homo sapiens Protein OS-9 Proteins 0.000 description 2
101000819227 Homo sapiens Protein YIF1A Proteins 0.000 description 2
101001126414 Homo sapiens Proteolipid protein 2 Proteins 0.000 description 2
101000612997 Homo sapiens Tetraspanin-5 Proteins 0.000 description 2
108010048829 Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels Proteins 0.000 description 2
102000009453 Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels Human genes 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
108090000862 Ion Channels Proteins 0.000 description 2
102000004310 Ion Channels Human genes 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
101100227177 Mus musculus Fkbp10 gene Proteins 0.000 description 2
101000819440 Mus musculus Frizzled-1 Proteins 0.000 description 2
101100070244 Mus musculus Hcn3 gene Proteins 0.000 description 2
101000649994 Mus musculus WW domain-binding protein 1 Proteins 0.000 description 2
241000187479 Mycobacterium tuberculosis Species 0.000 description 2
208000031888 Mycoses Diseases 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
108010033276 Peptide Fragments Proteins 0.000 description 2
102000007079 Peptide Fragments Human genes 0.000 description 2
102100021294 Protein YIF1A Human genes 0.000 description 2
101710201576 Putative membrane protein Proteins 0.000 description 2
108091034057 RNA (poly(A)) Proteins 0.000 description 2
206010063837 Reperfusion injury Diseases 0.000 description 2
241000242680 Schistosoma mansoni Species 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
208000006011 Stroke Diseases 0.000 description 2
208000007536 Thrombosis Diseases 0.000 description 2
208000025865 Ulcer Diseases 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
241000700605 Viruses Species 0.000 description 2
230000009471 action Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000002730 additional effect Effects 0.000 description 2
239000000556 agonist Substances 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000003466 anti-cipated effect Effects 0.000 description 2
230000007416 antiviral immune response Effects 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
108091008324 binding proteins Proteins 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
230000003915 cell function Effects 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
238000001516 cell proliferation assay Methods 0.000 description 2
208000015114 central nervous system disease Diseases 0.000 description 2
230000035605 chemotaxis Effects 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
238000010367 cloning Methods 0.000 description 2
239000002537 cosmetic Substances 0.000 description 2
238000002316 cosmetic surgery Methods 0.000 description 2
230000000139 costimulatory effect Effects 0.000 description 2
230000016396 cytokine production Effects 0.000 description 2
238000004163 cytometry Methods 0.000 description 2
230000007423 decrease Effects 0.000 description 2
210000004443 dendritic cell Anatomy 0.000 description 2
238000001514 detection method Methods 0.000 description 2
210000001671 embryonic stem cell Anatomy 0.000 description 2
210000003038 endothelium Anatomy 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
238000006911 enzymatic reaction Methods 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
102000044072 human ANGPT1 Human genes 0.000 description 2
102000045041 human OS9 Human genes 0.000 description 2
102000047311 human PLP2 Human genes 0.000 description 2
102000051109 human REEP5 Human genes 0.000 description 2
102000055465 human TSPAN5 Human genes 0.000 description 2
230000036039 immunity Effects 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
230000008611 intercellular interaction Effects 0.000 description 2
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
210000000066 myeloid cell Anatomy 0.000 description 2
210000003061 neural cell Anatomy 0.000 description 2
201000001119 neuropathy Diseases 0.000 description 2
230000007823 neuropathy Effects 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
235000016709 nutrition Nutrition 0.000 description 2
239000002245 particle Substances 0.000 description 2
208000027232 peripheral nervous system disease Diseases 0.000 description 2
208000033808 peripheral neuropathy Diseases 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
238000012545 processing Methods 0.000 description 2
210000001236 prokaryotic cell Anatomy 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
230000009772 tissue formation Effects 0.000 description 2
230000008467 tissue growth Effects 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
230000009466 transformation Effects 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
231100000397 ulcer Toxicity 0.000 description 2
230000003827 upregulation Effects 0.000 description 2
239000004474 valine Substances 0.000 description 2
125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
230000029663 wound healing Effects 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 1
LEVWYRKDKASIDU-OLPSTFOWSA-N (2R)-2-amino-3-[[(2R)-2-amino-2-carboxyethyl]di(35S)sulfanyl]propanoic acid Chemical compound C([C@@H](C(=O)O)N)[35S]SC[C@@H](C(=O)O)N LEVWYRKDKASIDU-OLPSTFOWSA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
108010029607 4-nitrophenyl-alpha-glucosidase Proteins 0.000 description 1
101100178313 Aedes aegypti HP-I gene Proteins 0.000 description 1
206010001488 Aggression Diseases 0.000 description 1
206010027654 Allergic conditions Diseases 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
GOVUDFOGXOONFT-VEVYYDQMSA-N Asn-Arg-Thr Chemical group [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GOVUDFOGXOONFT-VEVYYDQMSA-N 0.000 description 1
KXFCBAHYSLJCCY-ZLUOBGJFSA-N Asn-Asn-Ser Chemical group [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O KXFCBAHYSLJCCY-ZLUOBGJFSA-N 0.000 description 1
SPIPSJXLZVTXJL-ZLUOBGJFSA-N Asn-Cys-Ser Chemical group NC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O SPIPSJXLZVTXJL-ZLUOBGJFSA-N 0.000 description 1
QRHYAUYXBVVDSB-LKXGYXEUSA-N Asn-Cys-Thr Chemical group [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QRHYAUYXBVVDSB-LKXGYXEUSA-N 0.000 description 1
FTCGGKNCJZOPNB-WHFBIAKZSA-N Asn-Gly-Ser Chemical group NC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O FTCGGKNCJZOPNB-WHFBIAKZSA-N 0.000 description 1
SUEIIIFUBHDCCS-PBCZWWQYSA-N Asn-His-Thr Chemical group [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SUEIIIFUBHDCCS-PBCZWWQYSA-N 0.000 description 1
SEKBHZJLARBNPB-GHCJXIJMSA-N Asn-Ile-Ser Chemical group [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O SEKBHZJLARBNPB-GHCJXIJMSA-N 0.000 description 1
IBLAOXSULLECQZ-IUKAMOBKSA-N Asn-Ile-Thr Chemical group C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC(N)=O IBLAOXSULLECQZ-IUKAMOBKSA-N 0.000 description 1
COWITDLVHMZSIW-CIUDSAMLSA-N Asn-Lys-Ser Chemical group [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O COWITDLVHMZSIW-CIUDSAMLSA-N 0.000 description 1
KEUNWIXNKVWCFL-FXQIFTODSA-N Asn-Met-Ser Chemical group [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O KEUNWIXNKVWCFL-FXQIFTODSA-N 0.000 description 1
UXHYOWXTJLBEPG-GSSVUCPTSA-N Asn-Thr-Thr Chemical group [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UXHYOWXTJLBEPG-GSSVUCPTSA-N 0.000 description 1
208000034172 Autoimmune Experimental Myasthenia Gravis Diseases 0.000 description 1
208000030767 Autoimmune encephalitis Diseases 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
241000255789 Bombyx mori Species 0.000 description 1
208000010392 Bone Fractures Diseases 0.000 description 1
206010065553 Bone marrow failure Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
102000001902 CC Chemokines Human genes 0.000 description 1
108010040471 CC Chemokines Proteins 0.000 description 1
108050006947 CXC Chemokine Proteins 0.000 description 1
102000019388 CXC chemokine Human genes 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
206010007134 Candida infections Diseases 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
206010007710 Cartilage injury Diseases 0.000 description 1
108090000994 Catalytic RNA Proteins 0.000 description 1
102000053642 Catalytic RNA Human genes 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000003044 Closed Fractures Diseases 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
206010010099 Combined immunodeficiency Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
206010011968 Decreased immune responsiveness Diseases 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
208000009386 Experimental Arthritis Diseases 0.000 description 1
206010015866 Extravasation Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 description 1
208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
206010019196 Head injury Diseases 0.000 description 1
208000031220 Hemophilia Diseases 0.000 description 1
208000009292 Hemophilia A Diseases 0.000 description 1
208000028782 Hereditary disease Diseases 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 1
101000799972 Homo sapiens Alpha-2-macroglobulin Proteins 0.000 description 1
101000765010 Homo sapiens Beta-galactosidase Proteins 0.000 description 1
101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
101000864089 Homo sapiens HLA class II histocompatibility antigen, DP alpha 1 chain Proteins 0.000 description 1
101000930802 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 1 chain Proteins 0.000 description 1
101000968032 Homo sapiens HLA class II histocompatibility antigen, DR beta 3 chain Proteins 0.000 description 1
101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
101001010568 Homo sapiens Interleukin-11 Proteins 0.000 description 1
101001055216 Homo sapiens Interleukin-9 Proteins 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
102000004388 Interleukin-4 Human genes 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
241000222722 Leishmania <genus> Species 0.000 description 1
206010065433 Ligament rupture Diseases 0.000 description 1
206010024774 Localised infection Diseases 0.000 description 1
208000004852 Lung Injury Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
206010049567 Miller Fisher syndrome Diseases 0.000 description 1
101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
208000001089 Multiple system atrophy Diseases 0.000 description 1
101001044384 Mus musculus Interferon gamma Proteins 0.000 description 1
101001055215 Mus musculus Interleukin-9 Proteins 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
208000002565 Open Fractures Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
101150012195 PREB gene Proteins 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
208000010886 Peripheral nerve injury Diseases 0.000 description 1
102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
208000013544 Platelet disease Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
101800001357 Potential peptide Proteins 0.000 description 1
102400000745 Potential peptide Human genes 0.000 description 1
208000004210 Pressure Ulcer Diseases 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102000002067 Protein Subunits Human genes 0.000 description 1
108010001267 Protein Subunits Proteins 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
108091005682 Receptor kinases Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241000235343 Saccharomycetales Species 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
101100431523 Schizosaccharomyces pombe (strain 972 / ATCC 24843) SPBC119.09c gene Proteins 0.000 description 1
241000235345 Schizosaccharomycetaceae Species 0.000 description 1
102000003800 Selectins Human genes 0.000 description 1
108090000184 Selectins Proteins 0.000 description 1
108091081021 Sense strand Proteins 0.000 description 1
206010053879 Sepsis syndrome Diseases 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
208000029033 Spinal Cord disease Diseases 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
241000282887 Suidae Species 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
101710137500 T7 RNA polymerase Proteins 0.000 description 1
208000000491 Tendinopathy Diseases 0.000 description 1
206010043255 Tendonitis Diseases 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
206010069363 Traumatic lung injury Diseases 0.000 description 1
241000209140 Triticum Species 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
206010054880 Vascular insufficiency Diseases 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
241000269370 Xenopus <genus> Species 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
201000009961 allergic asthma Diseases 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
235000005550 amino acid supplement Nutrition 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
230000003321 amplification Effects 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
230000002491 angiogenic effect Effects 0.000 description 1
230000003172 anti-dna Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
230000030741 antigen processing and presentation Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
238000013459 approach Methods 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
238000007630 basic procedure Methods 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
208000015294 blood coagulation disease Diseases 0.000 description 1
230000008468 bone growth Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000003327 cancerostatic effect Effects 0.000 description 1
201000003984 candidiasis Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
210000004903 cardiac system Anatomy 0.000 description 1
208000003295 carpal tunnel syndrome Diseases 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
230000034196 cell chemotaxis Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000008614 cellular interaction Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
230000009852 coagulant defect Effects 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
230000019771 cognition Effects 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
208000018631 connective tissue disease Diseases 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 1
102000003675 cytokine receptors Human genes 0.000 description 1
108010057085 cytokine receptors Proteins 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
235000013367 dietary fats Nutrition 0.000 description 1
230000002222 downregulating effect Effects 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
210000003989 endothelium vascular Anatomy 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000006862 enzymatic digestion Effects 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000000267 erythroid cell Anatomy 0.000 description 1
230000000925 erythroid effect Effects 0.000 description 1
210000003013 erythroid precursor cell Anatomy 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000001400 expression cloning Methods 0.000 description 1
230000036251 extravasation Effects 0.000 description 1
208000030533 eye disease Diseases 0.000 description 1
230000020764 fibrinolysis Effects 0.000 description 1
239000003527 fibrinolytic agent Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
235000012041 food component Nutrition 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
238000007429 general method Methods 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
238000012248 genetic selection Methods 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000037308 hair color Effects 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
238000013537 high throughput screening Methods 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
239000000710 homodimer Substances 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
102000049437 human A2M Human genes 0.000 description 1
102000043557 human IFNG Human genes 0.000 description 1
102000049885 human IL11 Human genes 0.000 description 1
102000052627 human IL9 Human genes 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
230000003463 hyperproliferative effect Effects 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
208000036260 idiopathic disease Diseases 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000008629 immune suppression Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
230000001861 immunosuppressant effect Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000007574 infarction Effects 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
208000000509 infertility Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
231100000535 infertility Toxicity 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940028885 interleukin-4 Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
108010028930 invariant chain Proteins 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
208000012947 ischemia reperfusion injury Diseases 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
238000001155 isoelectric focusing Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
231100000225 lethality Toxicity 0.000 description 1
210000004523 ligament cell Anatomy 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000005228 liver tissue Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
231100000515 lung injury Toxicity 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
230000003526 lymphopoietic effect Effects 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000013160 medical therapy Methods 0.000 description 1
210000003593 megakaryocyte Anatomy 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
210000004296 naive t lymphocyte Anatomy 0.000 description 1
201000009240 nasopharyngitis Diseases 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
201000008383 nephritis Diseases 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
235000003170 nutritional factors Nutrition 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
230000000771 oncological effect Effects 0.000 description 1
210000000287 oocyte Anatomy 0.000 description 1
230000011164 ossification Effects 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
210000002997 osteoclast Anatomy 0.000 description 1
230000002188 osteogenic effect Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
244000045947 parasite Species 0.000 description 1
201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
230000007170 pathology Effects 0.000 description 1
208000028169 periodontal disease Diseases 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
239000002644 phorbol ester Substances 0.000 description 1
239000008055 phosphate buffer solution Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000019612 pigmentation Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000027317 positive regulation of immune response Effects 0.000 description 1
229910001414 potassium ion Inorganic materials 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
235000005974 protein supplement Nutrition 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
208000005069 pulmonary fibrosis Diseases 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
230000001603 reducing effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000002629 repopulating effect Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
238000002271 resection Methods 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
201000006845 reticulosarcoma Diseases 0.000 description 1
208000029922 reticulum cell sarcoma Diseases 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
230000033764 rhythmic process Effects 0.000 description 1
108091092562 ribozyme Proteins 0.000 description 1
238000005185 salting out Methods 0.000 description 1
239000012488 sample solution Substances 0.000 description 1
238000005070 sampling Methods 0.000 description 1
230000037390 scarring Effects 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
239000003352 sequestering agent Substances 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
230000003584 silencer Effects 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
230000021595 spermatogenesis Effects 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
230000003068 static effect Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
210000002536 stromal cell Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
231100000617 superantigen Toxicity 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
201000004415 tendinitis Diseases 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229960000103 thrombolytic agent Drugs 0.000 description 1
238000001890 transfection Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
230000001875 tumorinhibitory effect Effects 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
230000002792 vascular Effects 0.000 description 1
208000023577 vascular insufficiency disease Diseases 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Definitions

Fig. 40 illustrates the hydrophobicity/hydrophilicity profile of the protein encoded by clone HP10663.
Fig. 41 illustrates the hydrophobicity/hydrophilicity profile of the protein encoded by clone HP03165.
Fig. 48 illustrates the hydrophobicity/hydrophilicity profile of the protein encoded by clone HP10673.
tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class I ⁇ chain protein and ⁇ 2 microglobulin protein or an MHC class II chain protein and an MHC class II /3 chain protein to thereby express MHC class I or MHC class II proteins on the cell surface.
nucleic acid encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class I ⁇ chain protein and ⁇ 2 microglobulin protein or an MHC class II chain protein and an MHC class II /3 chain protein to thereby express MHC class I or MHC class II proteins on the cell surface.
a protein of the present invention which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals.
Such a preparation employing a protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints.
De novo bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.
a protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes.
Proteins of the present invention may also exhibit anti-inflammatory activity.
the anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell- cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response.
⁇ HP10636> (SEQ ID NOS: 66, 76, and 86) Determination of the whole base sequence of the cDNA insert of clone HP10636 obtained from cDNA library of human fibrosarcoma cell line HT-1080 revealed the structure consisting of a 179-bp 5 ' -untranslated region, a 1278-bp ORF, and a 255-bp 3 '-untranslated region.
the ORF encodes a protein consisting of 425 amino acid residues and there existed ten putative transmembrane domains.
Figure 26 depicts the hydrophobicity/hydrophilicity profile, obtained by the Kyte-Doolittle method, of the present protein. In vitro translation resulted in formation of a translation product of high molecular weight.
the search of the GenBank using the base sequences of the present cDNA has revealed the registration of sequences that shared a homology of 90% or more (for example, Accession No. R09702) among ESTs. However, since they are partial sequences, it can not be judged whether or not they encode the same protein as the protein of the present invention.
Table 26 shows the comparison between amino acid sequences of the human protein of the present invention (HS) and the Schizosaccharomyces pombe hypothetical protein (SP) .
the marks of -, *, and . represent a gap, an amino acid residue identical with that of the protein of the present invention, and an amino acid residue similar to that of the protein of the present invention, respectively.
the both proteins shared a homology of 43.4% in the entire region.
the search of the GenBank using the base sequences of the present cDNA has revealed the registration of sequences that shared a homology of 90% or more (for example, Accession No. AA043039) among ESTs. However, since they are partial sequences, it can not be judged whether or not they encode the same protein as the protein of the present invention.
⁇ HP10665> (SEQ ID NOS: 124, 134, and 144) Determination of the whole base sequence of the cDNA insert of clone HP10665 obtained from cDNA library of human fibrosarcoma cell line HT-1080 revealed the structure consisting of a 31-bp 5' -untranslated region, a 744-bp ORF, and a 142-bp 3'-untranslated region.
the ORF encodes a protein consisting of 247 amino acid residues and there existed a putative secretory signal at the N-terminus.
Figure 44 depicts the hydrophobicity/hydrophilicity profile, obtained by the Kyte-Doolittle method, of the present protein.
the search of the GenBank using the base sequences of the present cDNA has revealed the registration of sequences that shared a homology of 90% or more (for example, Accession No. R96413) among ESTs. However, since they are partial sequences, it can not be judged whether or not they encode the same protein as the protein of the present invention.
the present invention also provides genes corresponding to the polynucleotide sequences disclosed herein.
“Corresponding genes” are the regions of the genome that are transcribed to produce the mRNAs from which cDNA polynucleotide sequences are derived and may include contiguous regions of the genome necessary for the regulated expression of such genes. Corresponding genes may therefore include but are not limited to coding sequences, 5 ' and 3 ' untranslated regions, alternatively spliced exons, introns, promoters, enhancers, and silencer or suppressor elements. The corresponding genes can be isolated in accordance with known methods using the sequence information disclosed herein.
the present invention also includes polynucleotides capable of hybridizing under reduced stringency conditions, more preferably stringent conditions, and most preferably highly stringent conditions, to polynucleotides described herein.
stringency conditions are shown in the Table 32 below: highly stringent conditions are those that are at least as stringent as, for example, conditions A-F; stringent conditions are at least as stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Immunology (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

EP99972227A 1998-11-17 1999-11-17 Menschliche proteine mit hydrofoben domänen und dnas dafür kodierend Withdrawn EP1161536A1 (de)

Applications Claiming Priority (11)

Application Number	Priority Date	Filing Date	Title
JP32625598A JP2007222001A (ja)	1998-11-17	1998-11-17	疎水性ドメインを有するヒトタンパク質及びそれをコードするｄｎａ
JP32625598		1998-11-17
JP36431598		1998-12-22
JP36431598		1998-12-22
JP6981199		1999-03-16
JP6981199		1999-03-16
JP11929999		1999-04-27
JP119299		1999-04-27
JP13816999		1999-05-19
JP13816999		1999-05-19
PCT/JP1999/006412 WO2000029448A2 (en)	1998-11-17	1999-11-17	Human proteins having hydrophobic domains and dnas encoding these proteins

Publications (1)

Publication Number	Publication Date
EP1161536A1 true EP1161536A1 (de)	2001-12-12

Family

ID=27524206

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP99972227A Withdrawn EP1161536A1 (de)	1998-11-17	1999-11-17	Menschliche proteine mit hydrofoben domänen und dnas dafür kodierend

Country Status (3)

Country	Link
EP (1)	EP1161536A1 (de)
AU (1)	AU1181900A (de)
WO (1)	WO2000029448A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19806581A1 (de) *	1998-02-17	1999-10-21	Forschungszentrum Juelich Gmbh	Sequenzen eines Ih-Ionenkanals und deren Verwendung
US6902892B1 (en)	1998-10-19	2005-06-07	Diadexus, Inc.	Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
EP1159413A4 (de) *	1999-02-26	2005-12-14	Millennium Pharm Inc	Sekretierte proteine und ihre verwendungen
AU4456800A (en) *	1999-04-15	2000-11-02	Icagen, Inc.	Human hac3
AU4484400A (en) *	1999-04-23	2000-11-10	University Of Washington	Prostate-specific polynucleotides, polypeptides and their methods of use
ATE368110T1 (de) *	1999-07-20	2007-08-15	Genentech Inc	Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
EP1268506A4 (de) *	1999-07-30	2004-07-28	Millennium Pharm Inc	Sekret-proteine und ihre verwendung
KR100543857B1 (ko) *	1999-09-01	2006-01-23	제넨테크, 인크.	혈관신생 및 심혈관형성의 촉진 또는 억제
HUP0203408A3 (en) *	1999-12-09	2005-01-28	Sankyo Co	Method of testing remedy or preventive for hyperlipemia
AU2001283872A1 (en)	2000-06-21	2002-01-02	Bayer Aktiengesellschaft	Regulation of human eosinophil serine protease 1-like enzyme
AU2002240745A1 (en)	2001-03-07	2002-09-19	Andre Schuh	Diagnosis and treatment of blood disorders
EP1409676A2 (de) *	2001-03-07	2004-04-21	Andre Schuh	Nukleinsäuremoleküle cd109, polypeptide, und verfahren zur deren anwendung
CA2445171A1 (en) *	2001-04-24	2002-10-31	Mcgill University	A 150 kda tgf-beta 1 accessory receptor acting as a negative modulator of tgf-beta signaling
AU2003291625B2 (en) *	2002-09-16	2009-10-08	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
FR2849055A1 (fr) *	2002-12-18	2004-06-25	Exonhit Therapeutics Sa	Nouvelle cible moleculaire de l'angiogenese et utilisations
AU2005316169B2 (en)	2004-12-13	2011-11-17	Alethia Biotherapeutics Inc.	Polynucleotides and polypeptide sequences involved in the process of bone remodeling
JP4965326B2 (ja) *	2007-05-01	2012-07-04	独立行政法人科学技術振興機構	生理活性蛋白質の分泌を促進する新規な遺伝子ファミリー

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030092175A1 (en) *	1996-11-13	2003-05-15	Seishi Kato	Human proteins having transmembrane domains and dnas encoding these proteins

1999
- 1999-11-17 WO PCT/JP1999/006412 patent/WO2000029448A2/en not_active Ceased
- 1999-11-17 AU AU11819/00A patent/AU1181900A/en not_active Abandoned
- 1999-11-17 EP EP99972227A patent/EP1161536A1/de not_active Withdrawn

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0029448A3 *

Also Published As

Publication number	Publication date
WO2000029448A3 (en)	2001-12-27
WO2000029448A2 (en)	2000-05-25
AU1181900A (en)	2000-06-05

Legal Events

Date	Code	Title	Description
2001-10-26	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2001-12-12	17P	Request for examination filed	Effective date: 20010615
2001-12-12	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2001-12-12	AX	Request for extension of the european patent	Free format text: AL;LT;LV;MK;RO;SI
2002-02-27	D17D	Deferred search report published (deleted)
2004-09-10	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN
2004-10-27	18W	Application withdrawn	Effective date: 20040416

Publication	Publication Date	Title
WO2001049728A2 (en)	2001-07-12	HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
EP1100898A2 (de)	2001-05-23	Menschliche proteine mit hydrofoben domänen und dafür kodierende dnas
WO2000029448A2 (en)	2000-05-25	Human proteins having hydrophobic domains and dnas encoding these proteins
WO2001012660A2 (en)	2001-02-22	HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
WO2001002563A2 (en)	2001-01-11	HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
WO1997033993A1 (en)	1997-09-18	Human membrane antigen tm4 superfamily protein and dna encoding this protein
EP1056847A2 (de)	2000-12-06	Menschliche proteine mit transmembranären domäne und deren kodierende nukleinsäuren
EP1200582A2 (de)	2002-05-02	Menschliche proteine mit hydrofoben domänen und dnas dafür kodierend
WO2000000506A2 (en)	2000-01-06	Human proteins having hydrophobic domains and dnas encoding these proteins
WO1999010490A1 (en)	1999-03-04	Human galectin-9-like proteins and cdnas encoding these proteins
WO1999018204A2 (en)	1999-04-15	HUMAN PROTEINS HAVING SECRETORY SIGNAL SEQUENCES AND cDNAS ENCODING THESE PROTEINS
AU1175199A (en)	1999-06-15	Human proteins having transmembrane domains and dnas encoding these proteins
EP1021530A1 (de)	2000-07-26	PROTEINEN ÄHNLICH ZU DEM MENSCHLICHEN KOMPLEMENT FAKTOR H UND cDNAs KODIEREND FÜR DIESE PROTEINEN
AU9283298A (en)	1999-04-27	Human proteins having transmembrane domains and cdnas encoding these proteins
US6500939B1 (en)	2002-12-31	cDNAs coding for human proteins having transmembrane domains
WO2001000824A2 (en)	2001-01-04	HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
EP1021531A2 (de)	2000-07-26	Humane proteine mit transmembran-domänen und dnas dafür kodierend
EP1090131A1 (de)	2001-04-11	Menschliche glycoproteaseähnliche proteine und dafür kodierende dna
US20040048339A1 (en)	2004-03-11	Human proteins having transmembrane domains and cDNAs encoding these proteins
WO1999055862A2 (en)	1999-11-04	Human proteins having transmembrane domains and dnas encoding these proteins